SLNO: Urgent Legal Alert for Soleno Investors! Act Now!

Company Overview & Recent Developments

Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company focused on rare diseases, notably Prader-Willi syndrome (PWS) (www.globenewswire.com) (www.globenewswire.com). Soleno’s lead drug, diazoxide choline extended-release (DCCR), was approved by the FDA on March 26, 2025 for hyperphagia (insatiable hunger) in PWS patients and launched commercially as VYKAT™ XR (www.globenewswire.com) (www.globenewswire.com). The U.S. launch saw rapid uptake – Soleno received ~1,250 patient start forms in nine months (over 12% of the addressable U.S. PWS market) and generated $190.4 million in 2025 net product revenue (www.globenewswire.com) (www.globenewswire.com). This swift success even turned Soleno profitable in 2025 (net income ~$20.9 million) (www.globenewswire.com) (www.globenewswire.com). However, investors now face an urgent legal alert: multiple law firms have announced a securities class action lawsuit alleging Soleno misled investors about VYKAT’s safety profile (www.globenewswire.com) (www.globenewswire.com). The complaint claims Soleno downplayed significant safety concerns (like severe fluid retention) in its Phase 3 trials, resulting in an inflated stock price that later collapsed when safety issues came to light (www.globenewswire.com) (www.globenewswire.com). Indeed, Soleno’s stock soared above $77 in mid-2025 but plunged nearly 50% by late 2025 after a short-seller report and adverse news, prompting shareholder litigation (www.globenewswire.com) (www.globenewswire.com). In this report, we examine Soleno’s fundamentals – from dividend policy and leverage to valuation – and highlight key risks, red flags, and open questions facing SLNO investors.

Dividend Policy & Yield

No Dividend: Soleno has never paid a dividend on its common stock and does not plan to pay dividends in the foreseeable future (www.sec.gov). As a clinical-stage biotech transitioning to commercial stage, it instead reinvests any earnings into operations and growth. The company’s loan covenants also restrict dividend payments, aligning with management’s policy of retaining capital for business needs (www.sec.gov) (www.sec.gov). Consequently, dividend yield is 0%, and income investors should not expect any near-term payouts. Metrics like FFO/AFFO (funds from operations) are not applicable here, as those are used for REITs and cash-flowing real estate firms, whereas Soleno only recently began generating operating cash flow from product sales. In short, SLNO is a pure growth play – investors’ return will come from stock price appreciation, not dividends (www.sec.gov) (www.sec.gov).

Leverage, Debt & Maturities

Debt Facility: Soleno’s balance sheet carries minimal debt relative to its cash. In December 2024, the company secured a loan facility of up to $200 million from Oxford Finance, of which $50 million was drawn upfront (www.globenewswire.com) (www.sec.gov). This venture debt is structured favorably: it has a 48-month interest-only period and a 5-year term (60 months), with maturity in late 2029 (extendable to 2030 if performance milestones are met) (www.sec.gov) (www.sec.gov). Specifically, if Soleno hit certain goals by Sept 30, 2026 (which it did, by obtaining FDA approval in March 2025), the loan’s interest-only period extends and final maturity moves out to Dec 2030 (www.sec.gov) (www.sec.gov). Interest rate on the debt is floating at 1-month SOFR + 5.50%, which equated to roughly ~10–11% in 2025 (www.sec.gov). Importantly, Soleno is in a net cash position: it ended 2025 with $506.1 million in cash, equivalents and marketable securities, vastly exceeding the ~$50 million debt outstanding (www.globenewswire.com) (www.globenewswire.com). This large cash war chest arose from prior equity raises (over $158 million raised at $46/share in mid-2024) and robust 2025 product sales (www.sec.gov) (www.globenewswire.com). With no principal repayments due until 2029+, Soleno’s near-term debt burden is very light. The Oxford loan does include typical covenants (limiting new debt, liens, asset sales, etc.) and had a minimum cash requirement if FDA approval was delayed, as well as a future minimum revenue covenant once additional tranches are drawn (www.sec.gov) (www.sec.gov). Since approval was achieved and Soleno has strong revenues, these covenants have not been restrictive. Overall, Soleno’s leverage is low, and its debt maturity profile is long-dated, affording management flexibility to invest in commercialization and pipeline expansion without imminent refinancing risk.

Coverage & Financial Strength

Soleno’s interest coverage and liquidity position appear very healthy. In 2025, the company incurred approximately $5.5 million in interest expense on its debt (www.globenewswire.com). This was easily covered by operating profits – notably Soleno generated $20.9 million in net income (www.globenewswire.com) – and even more so by interest income from its large cash investments. In fact, Soleno’s interest income ($17 million) far outweighed interest expense in 2025, resulting in net positive other income (www.globenewswire.com). With over half a billion dollars in cash on hand (www.globenewswire.com), Soleno can comfortably pay its interest (and eventual principal) obligations. The interest-only loan structure further minimizes cash outflow in the next few years, allowing the company to reinvest cash into growth. Key coverage ratios reflect this strength: for 2025, EBITDA was positive (a rarity for a young biotech) and interest coverage (EBIT/interest) was well above 4× by net income, and even higher by EBITDA given that net income already includes significant non-cash charges (www.globenewswire.com) (www.globenewswire.com). Liquidity coverage is also robust – current assets were $293.9M vs. only $18.7M in current liabilities at 2024’s end (www.globenewswire.com), and the cash balance grew further in 2025 thanks to operating cash flow and financing. Additionally, debt covenants require Soleno to maintain a base level of cash and (once more than $50M is drawn) a base level of revenue (www.sec.gov), both of which it comfortably satisfies. In short, Soleno demonstrates strong financial coverage of its obligations, supported by high cash reserves and the early profitability of VYKAT XR’s launch. This provides a buffer to weather any short-term setbacks or investing activities without liquidity strain.

Valuation & Comparables

At a share price around $49 (early April 2026), Soleno’s market capitalization is roughly $2.6–2.7 billion (finance.yahoo.com). This valuation reflects a rich multiple on the company’s current financials. Based on 2025 results, SLNO trades at ~13–14× trailing sales (market cap ~$2.6B vs. $190.4M revenue) and over 100× trailing earnings ( ~$2.6B / $20.9M net income ) (www.globenewswire.com) (www.globenewswire.com). Such elevated ratios are typical for a newly commercial biotech with a first-to-market therapy in an unmet-need condition – investors are pricing in significant growth potential. Soleno captured just ~12% of the U.S. PWS market by end-2025, leaving substantial room for revenue expansion as more patients initiate therapy (www.globenewswire.com). Analysts anticipate rapid growth in 2026 and beyond, which would bring these multiples down. For instance, if Soleno were to double or triple its patient base in the next few years (not unrealistic given ~20,000+ PWS patients in the U.S. and no alternative therapies (www.globenewswire.com) (www.globenewswire.com)), revenues could approach half a billion annually – bringing the price/sales multiple into the mid-single digits. That said, comparables in the orphan drug space still trade at high valuations: companies with successful rare-disease launches often command 8–12× forward sales in their early years, reflecting premium pricing power and limited competition. In Soleno’s case, no direct competitors exist yet for hyperphagia in PWS (VYKAT XR is the first approved treatment) (www.globenewswire.com) (www.globenewswire.com). This monopoly-like status supports a high valuation, as do Soleno’s newfound profitability and hefty cash position (which it has even used to initiate a $100M share buyback program in late 2025) (www.globenewswire.com). However, investors should recognize that much of Soleno’s value hinges on future growth execution. Any slowdown in adoption or safety setbacks (see Risks below) could challenge the lofty valuation. By traditional metrics (e.g. P/E), SLNO looks expensive, but for a rare disease leader at the cusp of global expansion, a growth-premium is expected. The stock’s volatility – from sub-$10 levels pre-approval to >$70 post-approval, then down to ~$50 – also reflects evolving perceptions of its true value. Peers’ high multiples suggest the market is willing to value Soleno on a longer-term earnings trajectory (e.g. a few years out) rather than today’s profits, given the strong first-year performance and orphan drug pricing dynamics.

Key Risks & Red Flags

Despite its successes, Soleno faces several risks and red flags that investors should weigh:

– Safety and Efficacy Concerns: The biggest overhang is VYKAT XR’s safety profile. Scorpion Capital’s short report (Aug 2025) alleged that Soleno’s drug poses a high risk of fluid overload (edema) and heart failure in PWS patients (kelo.com) (kelo.com). Indeed, fluid retention was a known side effect (~10% incidence) noted in trials (www.globenewswire.com), and tragically, Soleno disclosed in Sept 2025 that a patient died after taking DCCR (www.globenewswire.com). These events suggest the drug can have serious adverse outcomes, especially in a population prone to obesity-related complications. If further adverse events occur or safety signals worsen, doctors and caregivers may become hesitant to start or continue VYKAT XR therapy – jeopardizing Soleno’s growth. Regulators could also impose stronger warnings or require post-market studies. The class action lawsuit now alleges Soleno downplayed or concealed such safety issues during the trial and launch (www.globenewswire.com) (www.globenewswire.com). While the claims must be proven, they highlight a credibility risk: if Soleno’s management was overly optimistic or omitted material risks in communications, investor trust could erode.

– Single-Product Dependency: Soleno’s fortunes are tied almost entirely to VYKAT XR (DCCR). The company currently has no other marketed products and is only just beginning to explore DCCR in additional indications (www.globenewswire.com). This concentration risk means any hitch with VYKAT – be it a safety issue, loss of efficacy over time, manufacturing problem, or new competitor – would directly hit revenue. Notably, Soleno’s Phase 3 program had a rocky start: the initial trial in 2020 failed to meet its primary endpoint (significant improvement in hyperphagia) (investors.soleno.life), and approval was ultimately based on post-hoc analyses and extension study data. This could be a red flag about marginal efficacy – if the drug’s benefits in the real world are less robust than hoped (especially if some initial responders drop off), clinicians might reduce usage. So far, demand has been strong, but continuous real-world outcomes will determine if VYKAT XR remains the standard in PWS.

– Stock Volatility & Shareholder Dilution: SLNO has exhibited extreme volatility. The stock skyrocketed over 2024–2025 as investors anticipated approval, then tumbled ~27% in one day after Q3 2025 results acknowledged the short-seller’s report had dampened the launch momentum (www.globenewswire.com). Such swings can be emotionally challenging and risk causing momentum-driven selloffs. Past financing actions also raise some flags: Soleno’s share count expanded dramatically (from ~16.5M weighted shares in 2023 to ~52M in 2025) due to equity offerings and generous stock-based compensation (www.globenewswire.com) (www.globenewswire.com). For example, management’s performance RSUs tied to FDA filing/approval resulted in a staggering $100 million non-cash stock compensation expense in 2024 (www.globenewswire.com) (www.globenewswire.com) – effectively rewarding insiders while diluting shareholders. While incentivizing success is important, the magnitude of these awards and immediate post-approval stock sales by any insiders (if occurred) could concern investors. On the positive side, the late-2025 buyback indicates management believed the stock was undervalued after the pullback, but some might argue those funds could have been used for R&D or international expansion instead.

– Litigation and Regulatory Risk: The securities class action now underway is seeking damages for investors who bought SLNO at inflated prices in 2025 (www.globenewswire.com) (www.globenewswire.com). Such lawsuits are not uncommon after a steep stock drop, and often they get settled by insurance – but they can distract management and produce negative headlines. More critically, if any investigation (legal or regulatory) finds that Soleno withheld information about safety issues, it could lead to penalties or deeper scrutiny by the FDA. Given that VYKAT XR was approved under priority review with no advisory committee (www.pharmaceutical-technology.com) (kelo.com) (likely due to the unmet need), regulators will be closely monitoring its safety in the real-world. Any hint of non-compliance in trial disclosures or adverse event reporting would be a serious red flag.

– Future Competition & Market Dynamics: Although VYKAT XR currently has the PWS hyperphagia market to itself, other companies may re-attempt development of PWS drugs given Soleno’s success. Historically, candidates like leptin analogs and oxytocin analogs (e.g. an intranasal carbetocin) were studied in PWS but failed to gain approval. Soleno’s triumph could spark renewed interest from competitors or academic researchers. A superior therapy in the future – one with fewer side effects or greater efficacy – could erode Soleno’s market share. Furthermore, as an orphan drug, VYKAT XR commands a very high price (implied well over $200k per patient annually based on revenue/patient calculations). This invites scrutiny on payer coverage and off-label use; insurers appear broadly covering it (185+ million U.S. lives were covered by year-end) (www.globenewswire.com), but pressure on pricing or access could rise if budget impact grows. Any pushback from payers (strict prior authorizations or formulary hurdles) is another risk to watch if costs remain high.

In sum, Soleno’s investment case has two faces: on one hand a groundbreaking therapy with strong uptake and financial strength; on the other, a suite of risks from safety to single-product reliance that could derail its trajectory. Investors should monitor how the company addresses the red flags, such as openly communicating safety updates, diversifying its pipeline, and maintaining ethical governance – as these will be critical to sustaining confidence in SLNO.

Open Questions for Investors

As Soleno moves forward, several open questions remain:

– Legal Outcome: How will the securities class action resolve? If Soleno can demonstrate it adequately disclosed risks (clinical trial data did mention edema and other side effects), the case might be dismissed or settled quietly. However, a protracted lawsuit or large settlement could cost millions and divert attention. Investors await clarity on any evidence of intentional misstatements – a key determinant of liability (www.globenewswire.com) (www.globenewswire.com).

– Patient Retention & Safety Monitoring: Will VYKAT XR’s early users stay on therapy long-term? The Q3 2025 update noted increased discontinuations after the short-seller’s report sowed fear (www.globenewswire.com). In 2026, a key metric will be continuation rates – do most of the 859 patients active at 2025’s end remain on drug, and are new patients continuing to initiate at a high pace? Moreover, will ongoing pharmacovigilance uncover any more serious adverse events? An improved safety update (or lack of new incidents) would reassure the PWS community, whereas additional deaths or hospitalizations could sharply limit uptake.

– European and Global Expansion: Can Soleno replicate its U.S. success abroad? The company submitted a marketing application in the EU in mid-2025 (www.globenewswire.com). European Medicines Agency approval is uncertain, given the U.S. trial’s controversies. How will EU regulators weigh VYKAT’s risk-benefit, and might they require additional studies or restrictions? Approval in Europe (and other territories) could open sizable new markets, whereas rejection or delay would confine Soleno to the U.S. for longer. This question extends to pricing and reimbursement in different healthcare systems – will EU payers be as receptive to a high price for a rare disease drug?

– Pipeline and Diversification: What are Soleno’s plans for additional indications or new products? Management has hinted at testing DCCR (diazoxide choline) in other high-need rare diseases (www.globenewswire.com), but specifics are scant. Investors are curious if conditions like congenital hyperinsulinism, other genetic obesity syndromes, or metabolic disorders could benefit from DCCR’s mechanism. Progress on a pipeline would diversify revenue and extend patent utilization, reducing the single-product risk. Absent new programs, Soleno might consider using its cash for strategic acquisitions of complementary rare-disease assets – an avenue to accelerate growth. How effectively it deploys the >$500M cash balance (beyond the recent buyback) is an open question for 2026–2027.

– Long-Term Market Potential: Finally, what is the sustainable peak sales for VYKAT XR in PWS? After the initial bolus of patients is treated (many of whom have now started therapy), will growth plateau or continue steadily? Prader-Willi is an ultra-orphan condition (~1 in 15,000 births (www.globenewswire.com)), so new patient flow each year is limited. Soleno’s capture of 12% of patients in 9 months was impressive (www.globenewswire.com), but can it reach 30%, 50% or more of the total population over time? The answer depends on physician adoption, caregiver trust, and managing side effects. If the majority of PWS patients ultimately go on therapy, VYKAT XR could be a blockbuster (>$1B/year in revenue). If, however, a significant subset cannot tolerate the drug or opt out due to safety/efficacy concerns, peak sales might undershoot expectations. This ties back to safety transparency and real-world outcomes over the next 1–2 years.

In conclusion, Soleno Therapeutics has delivered a rare commercial win in a historically intractable disease, driving its stock to multi-billion valuation. Yet with great opportunity comes great responsibility – to ensure patient safety, to be forthright with investors, and to strategically secure the company’s future growth. Soleno investors should “act now” by staying informed: monitor the legal filings, follow medical updates on VYKAT XR, and evaluate management’s moves to broaden the pipeline. The coming quarters will be pivotal in proving whether SLNO’s current valuation is justified by durable success or if cautionary flags will limit its ascent. The urgent alert is a reminder that diligence is warranted, even amidst the excitement of a medical breakthrough. Investors must balance the promise of Soleno’s therapy against the perils flagged above – and decide whether SLNO remains a rewarding cure for portfolios or a case of running ahead of the fundamentals.

Sources: Soleno SEC filings, investor communications, and reputable financial media were used in compiling this report. Key information was drawn from Soleno’s 2024–2025 financial results (www.globenewswire.com) (www.globenewswire.com), the FDA approval announcement (www.globenewswire.com), the Oxford loan agreement terms (www.sec.gov) (www.sec.gov), and the Faruqi law firm’s class action notice outlining alleged misrepresentations (www.globenewswire.com) (www.globenewswire.com). Additional context on the Scorpion Capital short report and subsequent stock reaction was provided by Reuters (kelo.com) (kelo.com). These sources and others have been cited inline throughout the report for verification and reference.

For informational purposes only; not investment advice.